دورية أكاديمية
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
| العنوان: | Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial |
|---|---|
| المؤلفون: | Liu, X, Munro, APS, Wright, A, Feng, S, Janani, L, Aley, PK, Babbage, G, Baker, J, Baxter, D, Bawa, T, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Fox, L, Qureshi, E, Goodman, AL, Green, CA, Haughney, J, Hicks, A, Jones, CE, Kanji, N, van der Klaauw, AA, Libri, V, Llewelyn, MJ, Mansfield, R, Maallah, M, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Belhadef, HT, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Saralaya, D, Sharma, S, Sheridan, R, Stokes, M, Thomson, EC, Todd, S, Twelves, C, Read, RC, Charlton, S, Hallis, B, Ramsay, M, Andrews, N, Lambe, T, Nguyen-Van-Tam, JS, Cornelius, V, Snape, MD, Faust, SN |
| المصدر: | Journal of Infection , 87 (1) pp. 18-26. (2023) |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2023 |
| المجموعة: | University College London: UCL Discovery |
| مصطلحات موضوعية: | Antibodies, Boosters, COVID-19, Immunisation, Immunogenicity, SARS-CoV-2, T-Cells, Vaccination |
| الوصف: | Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were subsequently widely used for the third and fourth-dose vaccination campaigns in high-income countries. Real-world vaccine effectiveness against symptomatic infections following third doses declined during the Omicron wave. This report compares the immunogenicity and kinetics of responses to third doses of vaccines from day (D) 28 to D242 following third doses in seven study arms. Methods: The trial initially included ten experimental vaccine arms (seven full-dose, three half-dose) delivered at three groups of six sites. Participants in each site group were randomised to three or four experimental vaccines, or MenACWY control. The trial was stratified such that half of participants had previously received two primary doses of ChAdOx1 nCov-19 (Oxford–AstraZeneca; hereafter referred to as ChAd) and half had received two doses of BNT162b2 (Pfizer–BioNtech, hereafter referred to as BNT). The D242 follow-up was done in seven arms (five full-dose, two half-dose). The BNT vaccine was used as the reference as it was the most commonly deployed third-dose vaccine in clinical practice in high-income countries. The primary analysis was conducted using all randomised and baseline seronegative participants who were SARS-CoV-2 naïve during the study and who had not received a further COVID-19 vaccine for any reason since third dose randomisation. Results: Among the 817 participants included in this report, the median age was 72 years (IQR: 55–78) with 50.7% being female. The decay rates of anti-spike IgG between vaccines are different among both populations who received initial doses of ChAd/ChAd and BNT/BNT. In the population that previously received ChAd/ChAd, mRNA vaccines had the highest titre at D242 following their vaccine dose although Ad26. COV2. S (Janssen; hereafter referred to as Ad26) showed slower decay. For people ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://discovery.ucl.ac.uk/id/eprint/10171907/1/1-s2.0-S0163445323002475-main.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10171907Test/ |
| الإتاحة: | https://discovery.ucl.ac.uk/id/eprint/10171907/1/1-s2.0-S0163445323002475-main.pdfTest https://discovery.ucl.ac.uk/id/eprint/10171907Test/ |
| حقوق: | open |
| رقم الانضمام: | edsbas.EA87157 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |